Endo International plc announced that its Board of Directors has appointed Mark G. Barberio to serve as a director, effective February 19, 2020. Mr. Barberio has also been appointed to Endo's Audit and Nominating & Governance Committees. Mr. Barberio is the principal of Markapital, LLC, a business and merger & acquisition consulting firm.

Prior to founding Markapital, he led Mark IV, LLC (now Dayco, LLC), a global diversified manufacturing company, where he served in a number of leadership positions, including as its Co-Chief Executive Officer and Chief Financial Officer. Separately, Endo announced that Blaise Coleman will succeed Paul Campanelli as President and Chief Executive Officer and become a member of the Board of Directors effective March 6, 2020. Mr. Barberio becomes the sixth independent director on Endo's eight member Board, which also reflects the addition of Mr. Coleman.

Mr. Campanelli will continue to serve as Chairman of the Board. This appointment will complete the Chief Executive Officer succession plan that Endo announced in November 2019. Mr. Coleman has more than 20 years of pharmaceutical industry experience.

Prior to joining Endo in 2015, he held a number of leadership roles of increasing responsibility with AstraZeneca and Johnson & Johnson. Additionally, Mark Bradley will succeed Blaise Coleman as Executive Vice President and Chief Financial Officer. Mr. Bradley is currently Endo's Senior Vice President, Corporate Development & Treasurer.